FOLH1 and neoplasm: Therefore, in this study we set up to evaluate the potential of combining the PSMA-targeted alpha-emitting radioligand [212Pb]Pb-AB001 with BET inhibitors (AZD5153 or JQ1) in 2D monolayer cultures and 3D tumour spheroids to ultimately enhance therapeutic efficacy for mCRPC patients.